IMMUNOPRECISE ANTIBOD.
MindWalk operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its na… Read more
IMMUNOPRECISE ANTIBOD. (TQB) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, IMMUNOPRECISE ANTIBOD. (TQB) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
IMMUNOPRECISE ANTIBOD. - Net Assets Trend (None–None)
This chart illustrates how IMMUNOPRECISE ANTIBOD.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for IMMUNOPRECISE ANTIBOD. (None–None)
The table below shows the annual net assets of IMMUNOPRECISE ANTIBOD. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to IMMUNOPRECISE ANTIBOD.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
IMMUNOPRECISE ANTIBOD. Competitors by Market Cap
The table below lists competitors of IMMUNOPRECISE ANTIBOD. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Renergen Limited
PINK:RGNTF
|
$67.86 Million |
|
NET Power Inc.
NYSE:NPWR
|
$67.86 Million |
|
VirnetX Holding Corp Common Stock
NYSE:VHC
|
$67.88 Million |
|
Marco Polo Marine Ltd.
PINK:MRPMF
|
$67.88 Million |
|
Nalwa Sons Investments Limited
NSE:NSIL
|
$67.81 Million |
|
Total Bangun Persada Tbk
JK:TOTL
|
$67.81 Million |
|
289930
KQ:289930
|
$67.81 Million |
|
TTEC Holdings Inc
NASDAQ:TTEC
|
$67.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in IMMUNOPRECISE ANTIBOD.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares IMMUNOPRECISE ANTIBOD.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently IMMUNOPRECISE ANTIBOD. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares IMMUNOPRECISE ANTIBOD.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| IMMUNOPRECISE ANTIBOD. (TQB) | €- | N/A | N/A | $67.83 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |